Lloyd Inc. of Iowa
Complete recall history across all FDA and CPSC categories — 36 total recalls
Lloyd Inc. of Iowa appears in recall records across 1 category. This page consolidates all FDA food, drug, and medical device enforcement actions, plus CPSC consumer product recalls associated with this company. Recall data is sourced from openFDA and CPSC public databases.
Drug Recalls (36)
FDA drug safety enforcement actions by Lloyd Inc. of Iowa
| Date | Product | Reason | Class |
|---|---|---|---|
| Apr 1, 2013 | Lloyd Thyro-Tab 0.200 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 175 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.175 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.137 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP) , 125 mcg, RX only, 100 tablet... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.100 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.125 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.088 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP) , 75 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 100 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.112 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.075 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 200 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 88 mcg, RX only, 100 tablets ... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP) , 50 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 150 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 112 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Levothroid (levothyroxine sodium tablets, USP), 137 mcg, RX only, 100 tablets... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.150 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Apr 1, 2013 | Lloyd Thyro-Tab 0.050 mg., packaged in 150,000-tablet bulk drums (2/75,000-ta... | cGMP deviations; After quality review of stability failures in previous lots,... | Class II |
| Jul 25, 2012 | Thyro-Tab 0.050 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | Subpotent; 9-month stability interval | Class II |
| Jul 25, 2012 | Thyro-Tab 0.075 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | Subpotent; 9-month stability interval | Class II |
| Jul 25, 2012 | Levothroid (levothyroxine sodium tablets, USP), 50 mcg., 100-count bottles, R... | Subpotent; 9-month stability interval | Class II |
| Jul 25, 2012 | Levothroid (levothyroxine sodium tablets, USP), 75 mcg., 100-count bottles, R... | Subpotent; 9-month stability interval | Class II |
| Jul 9, 2012 | Thyro-Tab 0.088 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Thyro-Tab 0.300 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Thyro-Tab 0.125 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Levothroid (levothyroxine sodium tablets, USP), 50 mcg., 100-count bottles, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Thyro-Tab 0.112 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Levothroid (levothyroxine sodium tablets, USP), 300 mcg., 100-count bottles, ... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Thyro-Tab 0.050 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Levothroid (levothyroxine sodium tablets, USP), 88 mcg., 100-count bottles, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Levothroid (levothyroxine sodium tablets, USP),125 mcg., 100-count bottles, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Thyro-Tab 0.137 mg., packaged in 150,000-tablet bulk drums for repackaging, R... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Levothroid (levothyroxine sodium tablets, USP), 137 mcg., 100-count bottles, ... | cGMP Deviations; does not meet in process specification requirements | Class II |
| Jul 9, 2012 | Levothroid (levothyroxine sodium tablets, USP), 112 mcg., 100-count bottles, ... | cGMP Deviations; does not meet in process specification requirements | Class II |
Frequently Asked Questions
A high number of recalls does not necessarily indicate that a company is unsafe. Large manufacturers that produce thousands of products across multiple categories will statistically appear in recall databases more frequently. What matters more is the severity of each recall (Class I being the most serious), the speed of response, and whether the company proactively identified and addressed the issue. Companies with robust safety programs often catch problems earlier.
Food, drug, and medical device recall data comes from the FDA's openFDA enforcement database, which contains all FDA enforcement reports. Consumer product recall data comes from the U.S. Consumer Product Safety Commission (CPSC). Both sources are public government databases that are updated regularly. RecallCheck aggregates these sources to provide a unified view of a company's recall history.
The FDA classifies recalls into three categories. Class I is the most serious — there is a reasonable probability that use of or exposure to the product will cause serious adverse health consequences or death. Class II means the product may cause temporary or medically reversible health problems, or the probability of serious consequences is remote. Class III is the least serious — the product is unlikely to cause adverse health consequences. CPSC product recalls do not use this classification system.
Yes. You can search for any company using the firm/manufacturer pages for each category: Food Firms, Drug Firms, Device Firms, or Product Manufacturers. You can also use the search functionality on any browse page to find recalls by company name.
Explore More Recalls
Search recalls by category, state, reason, or firm across all our databases.